GlassScriptPhysician profile
Kimberly Nackord
NPI 1407305980
$1,058.90
in general payments reported to CMS, 2019-2025
21 companies · $701 in 2025
The $701 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $358 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $196.91 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $98.96 | 2024-2025 | |
| Glaxosmithkline, LLC. | $95.61 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $95.56 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $57.17 | 2024-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $53.54 | 2025 | Rexulti |
| Exact Sciences Corporation | $52.22 | 2024-2025 | Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $51.11 | 2025 | Pyrukynd |
| Novartis Pharmaceuticals Corporation | $44.88 | 2024-2025 | |
| Abbvie INC. | $42.58 | 2025 | |
| Janssen Pharmaceuticals, INC | $35.49 | 2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $30.21 | 2025 | |
| Insmed, INC. | $29.68 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $28.52 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $25.57 | 2024 | Otezla, Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $22.14 | 2025 | Heplisav-B |
| Lundbeck LLC | $20.61 | 2025 | Rexulti |
| Madrigal Pharmaceuticals | $20.18 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.68 | 2025 | |
| Inspire Medical Systems, INC. | $18.29 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Nackord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.